Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer : Institutional Experience |
Gogia, Ajay
(Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences)
Raina, Vinod (Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Deo, Suryanarayan Vishnu (Surgical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Shukla, Nootan Kumar (Surgical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Mohanti, Bidhu Kalyan (Radiation Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Sharma, Daya Nand (Radiation Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) |
1 | Baltali E, Altundag MK, Onat DA, et al (2002). Neoadjuvant chemotherapy with Taxotere-epirubicin-5-fluorouracil (TEF) in loco regionally advanced breast cancer: A preliminary report. Tumori, 88, 474-7. |
2 | Baselga J, Bradbury I, Eidtmann H, et al (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379, 633-8. DOI |
3 | Untch M, Loibl S, Bischoff J, et al (2012). Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 13, 135-9. DOI |
4 | Sikov WM, Dizon DS, Strenger R, et al (2009). Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol, 27, 4693-99. DOI |
5 | Sikov W, Berry DA, Perou CM, et al (2013). Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triplenegative breast cancer (TNBC): CALGB 40603 (Alliance). San Antonio Breast Cancer Symposium. Abstract, 5-14. |
6 | Yao X, Hosenpud J, Chitambar CR (2012). A phase ii study of concurrent docetaxel, epirubicin and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. J Cancer, 3, 145-51. DOI |
7 | Untch M, Rezai M, Loibl S, et al (2010). Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 28, 2024-31. DOI ScienceOn |
8 | von Minckwitz G, Eidtmann H, Rezai M, et al (2012). Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med, 366, 299-309. DOI |
9 | Von Minckwitz G, Kummel S, Vogel P, et al (2008). Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst, 100, 552-62. DOI ScienceOn |
10 | Papademetriou K, Ardavanis A, Kountourakis P (2010). Neoadjuvant chemotherapy for locally advanced breast cancer:Focus on chemotherapy and biological targeted treatments' armamentarium. J Thoracic Disease, 2, 160-8. |
11 | Gupta D, Raina V, Rath GK, et al (2011). Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapyin locally advanced breast cancer and comparison with anthracycline-based chemotherapies: Eight-year experience from single centre. Indian J Cancer, 48, 410-14. DOI |
12 | Manoharan N, Tyagi BB, Raina V (2010). Cancer incidences in rural Delhi-2004-05. Asian Pac J Cancer Prev, 11, 73-7. |
13 | Mathew J, Asgeirsson KS, Agrawal A, et al (2007). Neoadjuvant chemotherapy in locally advanced primary breast cancers: The Nottingham experience. EJSO, 33, 972-76. DOI ScienceOn |
14 | Deo SV, Bhutani M, Shukla NK, et al (2003). Randomized trial comparing neoadjuvant vs adjuvant chemotherapy in locally advanced breast cancer (T4bN0-2M0). J Surg Oncol, 84, 192-7. DOI |
15 | Phua CE, Bustam AZ, Yusof MM, et al (2012). Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. Asian Pac J Cancer Prev, 13, 4623-6. 과학기술학회마을 DOI |
16 | Pierga JY, Delaloge S, Espie M, et al (2010). A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat, 122, 429-37. DOI |
17 | Rastogi P, Anderson SJ, Bear HD, et al (2008). Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85. DOI ScienceOn |
18 | Bull JM, Tormey DC, Li SH (1978). A randomised comparative trial of adriamycine versus methotrexate in combinationdrug therapy. Cancer, 41, 1649-57. DOI |
19 | Cortazar P, Zhang L, Untch M, et al (2012). Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res, 18, 72-93. |
20 | Chopra R(2001).The Indian scene. J Clin Oncol, 19, 106-11. |
21 | Early Breast Cancer Trialists Collaborative Group (1998). Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet, 352, 930-42. DOI |
22 | Guarneri V, Frassoldati A, Bottini A, et al (2012). Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol, 30, 1989-99. DOI |
23 | Gianni L, Eiermann W, Semiglazov V, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84. DOI ScienceOn |
24 | Giordano SH (2003). Update on locally advanced breast cancer. The Oncologist, 8, 521-30. DOI |
25 | Gradishar WJ, Wedam SB, Jahanzeb M, et al (2005). Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol, 16, 1297-304. DOI |
26 | Raina V, Medhi K, Deo S (2007). Shukla NK, Mohanti BK, Rath GK. Outcome of combined modality treatment of 412 cases of locally advanced breast cancer (LABC): Data from a tertiary cancer center in India. Breast Cancer Res Treat, 106, 1-350 |
![]() |